Positive volume growth was observed in key therapies such as respiratory (13.2% yoy), anti-neoplastics (12.1% yoy) and cardiac (4.8% yoy) during September 2025
RedHill will receive $500,000 in guaranteed payments, including a $250,000 upfront payment and $250,000 in fixed payments due within 18 months
Conventional plasmids as a pharmaceutical material are not only suboptimal in safety and function, but exceedingly costly to produce, prohibitively
Furthering?U.S.-based?pharmaceutical?capacity?to?produce?critical respiratory medicines?
Lonza boosts TheraPEAK line with new Cytokines and AAV Medium for next-gen therapies
This collaboration aims to combine Molcure’s cutting-edge AI technology with Boehringer Ingelheim’s extensive expertise in drug discovery
It represents a 30% increase in the company’s production capacity and introduces a segment dedicated to highly potent active ingredients
Pioneering innovation aims to transform anticoagulant therapy and improve patient outcomes
Marks first international filing for Evofem’s single-dose oral treatment
Anti-microtubule binding region-tau antibody being investigated as a potential disease-modifying therapy to slow or delay progression of disease
Subscribe To Our Newsletter & Stay Updated
